Author/Authors :
Alavian، Seyed-Moayed نويسنده , , Hajarizadeh، Behzad نويسنده , , Bagheri-Lankarani، Kamran نويسنده , , Sharafi، Heidar نويسنده Molecular Division, Iran Hepatitis Network, Tehran, IR Iran , , Ebrahimi Daryani، Nasser نويسنده , , Merat، Shahin نويسنده , , Mohraz، Minoo نويسنده , , Mardani، Masoud نويسنده , , Fattahi moghadam، Mohamad Reza نويسنده , , Poustchi، Hossein نويسنده Digestive Disease Research Center, Tehran University of Medical Sciences, Tehran, Iran Poustchi, Hossein , Nikbin، Mehri نويسنده Middle East Liver Diseases (MELD) Center, Tehran, IR Iran , , Nabavi، Mahmood نويسنده , , Adibi، Peyman نويسنده , , Ziaee، Masood نويسنده Department of Internal Medicine, Hepatitis Research Center, Faculty of Medicine, Birjand University of Medical Sciences, Birjand, IR Iran , , Behnava، Bita نويسنده Baqiyatallah University of Medical Sciences, Baqiyatallah Research Center for Gastroenterology and Liver diseases, Tehran, IR Iran , , Rezaee-Zavareh، Mohammad Saeid نويسنده Students’ Research Committee, Baqiyatallah University of
Medical Sciences, Tehran, IR Iran , , Colombo، Massimo G. نويسنده , , Massoumi، Hatef نويسنده New York Associates in Gastroenterology, Bronx, New York, USA , , Bizri، Abdul Rahman نويسنده Division of Infectious Diseases, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon , , Eghtesad، Bijan نويسنده Cleveland Clinic, Cleveland, OH, USA , , Amiri، Majid نويسنده Hospices Civils de Lyon, Croix-Rousse Hospital, Department of Hepatology, Lyon, France Amiri, Majid , Namvar، Ali نويسنده Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, IR Iran , , Hesamizadeh، Khashayar نويسنده Middle East Liver Disease (MELD) Center, Tehran, IR Iran , , Malekzadeh، Reza نويسنده ,
Abstract :
Hepatitis C virus (HCV) infection is a major public health issue worldwide, including Iran. The new direct-acting antiviral agents (DAAs) with high efficacy have changed the landscape of HCV treatment. This guideline provides updated recommendations for clinical management of HCV infection in Iran. The recommendations of this guideline are based on international and national scientific evidences and consensus-based expert opinion. Scientific evidences were collected through a systematic review of studies that evaluated efficacy and safety of DAA regimens, using PubMed, Scopus and Web of Science. Expert opinion was based on the consensus of Iran Hepatitis Scientific Board (IHSB) in the 3rd national consensus on management of Hepatitis C in Iran, held on 22nd of July 2016. Pegylated Interferon alpha (PegIFN), Ribavirin (RBV), Sofosbuvir (SOF), Ledipasvir (LDV) and Daclatasvir (DCV) are currently available in Iran. Pre-treatment assessments include HCV RNA level, HCV genotype and resistance testing, assessment of liver fibrosis, and underlying diseases. In HCV genotype 1 and 4, DCV/SOF and LDV/SOF are recommended. In HCV genotype 2, SOF plus RBV and in HCV genotype 3, DCV/SOF is recommended. Additional care for underlying diseases should be considered. Affordable new HCV treatment regimens are available in Iran, providing an opportunity for HCV elimination. Recommendations provided in this current national guideline can facilitate evidence-based management of HCV infection.
